269 related articles for article (PubMed ID: 26568304)
1. CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.
Min B; Park H; Lee S; Li Y; Choi JM; Lee JY; Kim J; Choi YD; Kwon YG; Lee HW; Bae SC; Yun CO; Chung KC
Oncogene; 2016 Jul; 35(28):3718-28. PubMed ID: 26568304
[TBL] [Abstract][Full Text] [Related]
2. The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.
Zhang HT; Zeng LF; He QY; Tao WA; Zha ZG; Hu CD
Biochim Biophys Acta; 2016 Feb; 1863(2):335-46. PubMed ID: 26658161
[TBL] [Abstract][Full Text] [Related]
3. PINK1 phosphorylates transglutaminase 2 and blocks its proteasomal degradation.
Min B; Kwon YC; Choe KM; Chung KC
J Neurosci Res; 2015 May; 93(5):722-35. PubMed ID: 25557247
[TBL] [Abstract][Full Text] [Related]
4. E3 ubiquitin ligase CHIP interacts with C-type lectin-like receptor CLEC-2 and promotes its ubiquitin-proteasome degradation.
Shao M; Li L; Song S; Wu W; Peng P; Yang C; Zhang M; Duan F; Jia D; Zhang J; Wu H; Zhao R; Wang L; Ruan Y; Gu J
Cell Signal; 2016 Oct; 28(10):1530-6. PubMed ID: 27443248
[TBL] [Abstract][Full Text] [Related]
5. The E3 ubiquitin ligase CHIP selectively regulates mutant epidermal growth factor receptor by ubiquitination and degradation.
Chung C; Yoo G; Kim T; Lee D; Lee CS; Cha HR; Park YH; Moon JY; Jung SS; Kim JO; Lee JC; Kim SY; Park HS; Park M; Park DI; Lim DS; Jang KW; Lee JE
Biochem Biophys Res Commun; 2016 Oct; 479(2):152-158. PubMed ID: 27475501
[TBL] [Abstract][Full Text] [Related]
6. Reduction of transforming growth factor-beta type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma.
Fukasawa H; Yamamoto T; Fujigaki Y; Misaki T; Ohashi N; Takayama T; Suzuki S; Mugiya S; Oda T; Uchida C; Kitagawa K; Hattori T; Hayashi H; Ozono S; Kitagawa M; Hishida A
Int J Cancer; 2010 Oct; 127(7):1517-25. PubMed ID: 20073064
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
8. Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.
Liu C; Wang W; Parchim N; Irani RA; Blackwell SC; Sibai B; Jin J; Kellems RE; Xia Y
Hypertension; 2014 Feb; 63(2):353-61. PubMed ID: 24191290
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
Lee SH; Kang JH; Ha JS; Lee JS; Oh SJ; Choi HJ; Song J; Kim SY
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708896
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
Jang JH; Park JS; Lee TJ; Kwon TK
Cancer Lett; 2010 Jan; 287(2):224-30. PubMed ID: 19632032
[TBL] [Abstract][Full Text] [Related]
12. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
Verma A; Guha S; Wang H; Fok JY; Koul D; Abbruzzese J; Mehta K
Clin Cancer Res; 2008 Apr; 14(7):1997-2005. PubMed ID: 18381937
[TBL] [Abstract][Full Text] [Related]
13. TRIM65 promotes renal cell carcinoma through ubiquitination and degradation of BTG3.
Zhang Q; Li Y; Zhu Q; Xie T; Xiao Y; Zhang F; Li N; Deng K; Xin H; Huang X
Cell Death Dis; 2024 May; 15(5):355. PubMed ID: 38777825
[TBL] [Abstract][Full Text] [Related]
14. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.
Fan M; Park A; Nephew KP
Mol Endocrinol; 2005 Dec; 19(12):2901-14. PubMed ID: 16037132
[TBL] [Abstract][Full Text] [Related]
15. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
16. UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells.
Sane S; Hafner A; Srinivasan R; Masood D; Slunecka JL; Noldner CJ; Hanson AD; Kruisselbrink T; Wang X; Wang Y; Yin J; Rezvani K
Mol Oncol; 2018 Oct; 12(10):1753-1777. PubMed ID: 30107089
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of transglutaminase and ε (γ-glutamyl)-lysine in the Fisher-Lewis rat model of chronic allograft nephropathy.
Shrestha B; Butt I; Da Silva M; Sanchez-Lara A; Wagner B; Raftery A; Johnson T; Haylor J
Biomed Res Int; 2014; 2014():651608. PubMed ID: 25143942
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin E3 ligase CHIP promotes proteasomal degradation of the serine/threonine protein kinase PINK1 during staurosporine-induced cell death.
Yoo L; Chung KC
J Biol Chem; 2018 Jan; 293(4):1286-1297. PubMed ID: 29242192
[TBL] [Abstract][Full Text] [Related]
19. Stability of the cancer target DDIAS is regulated by the CHIP/HSP70 pathway in lung cancer cells.
Won KJ; Im JY; Kim BK; Ban HS; Jung YJ; Jung KE; Won M
Cell Death Dis; 2017 Jan; 8(1):e2554. PubMed ID: 28079882
[TBL] [Abstract][Full Text] [Related]
20. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth.
Jones RA; Kotsakis P; Johnson TS; Chau DY; Ali S; Melino G; Griffin M
Cell Death Differ; 2006 Sep; 13(9):1442-53. PubMed ID: 16294209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
